Biomarkers of Major Depressive Disorder: Knowing is Half the Battle
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a heterogeneous disease which is why there are currently no specific methods to accurately test the severity, endophenotype or therapy response. This lack of progress is partly attributed to the com-plexity and variability of depression, in association with analytical variability of clinical literature and the wide number of theoretically complex biomarkers. The literature accessible, indicates that markers involved in inflammatory, neuro-trophic and metabolic processes and components of neurotransmitters and neuroendocrine systems are rather strong indicators to be considered clinically and can be measured through genetic and epigenetic, transcriptomic and proteomic, metabolomics and neuroimaging assessments. Promising biologic systems/markers found were i.e., growth biomarkers, endocrine markers, oxidant stress markers, proteomic and chronic inflammatory markers, are discussed in this review. Several lines of evidence suggest that a portion of MDD is a dopamine agonist-responsive subtype. This review analyzes concise reports on the pathophysiological biomarkers of MDD and therapeutic reactions via peripheral developmental factors, inflammative cytokines, endocrine factors and metabolic markers. Various literatures also support that endocrine and metabolism changes are associated with MDD. Accumulating evidence suggests that at least a portion of MDD patients show characteristics pathological changes regarding different clinical pathological biomarkers. By this review we sum up all the different biomarkers playing an important role in the detection or treatment of the different patients suffering from MDD. The review also gives an overview of different biomarker's playing a potential role in modulating effect of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Depression and poor glycemic control: a meta-analytic review of the literature.
Lustman, P. J., Anderson, R. J., Freedland, K. E., de Groot, M., Carney, R. M., & Clouse, R. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.934 · Cited by 1,854
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129 · cited 1×
“Higher standards just or no gaps in European research [81].”
BackgroundStetler, C., & Miller, G. E. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31820ad12b · Cited by 1,123 · cited 1×
“these indicate that hypercortisolemia is linked with stress and a recurrent attenuation of cortisol awakening responses [111,112].”
BackgroundDiscovering Endophenotypes for Major Depression
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300506 · Cited by 1,123
Bak, L. K., Schousboe, A., & Waagepetersen, H. S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03913.x · Cited by 1,114
Evidence for an immune response in major depression: A review and hypothesis
Maes, M. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)00101-m · Cited by 1,003
Liu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · cited 1×
“relative to the controls on safe medicine [71-74].”
BackgroundHannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Castrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864
Bidirectional Association Between Depression and Metabolic Syndrome
Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012) · Diabetes Care · doi:10.2337/dc11-2055 · Cited by 772
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Sonner, Z., Wilder, E., Heikenfeld, J., Kasting, G., Beyette, F., Swaile, D., Sherman, F., Joyce, J., Hagen, J., Kelley-Loughnane, N., et al. (2015) · Biomicrofluidics · doi:10.1063/1.4921039 · Cited by 724
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 1×
“were also linked with treatment-emergent suicidality [33].”
Maes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Depressive disorders and immunity: 20 years of progress and discovery
Irwin, M. R., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.01.010 · Cited by 676
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666 · cited 2×
“A realistic solution to mental condition research (e.g., depression) by incorporating multiple layers of quantitative biologic and psychological contextual data into a framework is the Research Domain Criteria (RDoC) program of the National Institute of Health [35].”
BackgroundThe glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592 · cited 1×
“and non-depressed populations are not so large and significant [114], it may be more valuable to take modern genetic strategies such as polygenic scores [115] and telo-”
BackgroundA Meta-analysis of oxidative stress markers in depression
Liu, T., Zhong, S., Liao, X., Chen, J., He, T., Lai, S., & Jia, Y. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138904 · Cited by 485
Hypocretin (orexin) loss in Parkinson's disease
Fronczek, R., Overeem, S., Lee, S. Y. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., Lammers, G. J., & Swaab, D. F. (2007) · Brain · doi:10.1093/brain/awm090 · Cited by 463 · cited 1×
“Urinal rates [102] and serum were higher”
Neuroendocrine aspects of hypercortisolism in major depression
Parker, K. J., Schatzberg, A. F., & Lyons, D. M. (2003) · Hormones and Behavior · doi:10.1016/s0018-506x(02)00016-8 · Cited by 455 · cited 2×
“cortisol rates can indicate fewer psychological reaction [108] and more antidepressant treatment [113,110] in fact.”
BackgroundDysregulation of the fibroblast growth factor system in major depression
Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406788101 · Cited by 424 · cited 1×
“relative to the controls on safe medicine [71-74].”
BackgroundFeyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421 · cited 1×
“Synaptic plasticity and movement control by BDNF [59].”
BackgroundBiomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415 · cited 1×
“malady activity, maybe influenced by the requirement to get speedy quantitative indications of drug action to hurry the event of recent anti-depressive agents [1].”
BackgroundAagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., Patel, S., Cutting, M., Madden, T., Hamilton, H., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-220806 · Cited by 383
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., Schatzberg, A. F., Myers, R. M., Akil, H., & Watson, S. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.44 · Cited by 372 · cited 1×
“cial to the role as biomarkers for their presence in brain and peripheral circulation [67-70].”
BackgroundSex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250 · cited 3×
“Sequenced Treatment Alternatives to Relieve Depression (STAR*D), STAR*D study reported by [32], reported the response or outcome of SSRI citalopram, subsequent medicinal therapies, or combinations of therapy.”
BackgroundEpigenetic mechanisms of depression
Nestler, E. J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4291 · Cited by 217
Duman, R. S. (2014) · Depression and Anxiety · doi:10.1002/da.22227 · Cited by 213
A meta-analysis of chemokines in major depression
Eyre, H. A., Air, T., Pradhan, A., Johnston, J., Lavretsky, H., Stuart, M. J., & Baune, B. T. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.006 · Cited by 188 · cited 1×
“The regularly and consistently increased in case of depression is IL-6 and C-reactive protein [78-80].”
BackgroundHippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder
Gaughran, F., Payne, J., Sedgwick, P. M., Cotter, D., & Berry, M. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.04.008 · Cited by 178
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149 · cited 1×
“duction of new, non-monoamine-based depression approaches, including the melatonergic mechanism [14] or glutamate method [15,16], has become increasingly”
BackgroundPlasma lipidomics reveals potential lipid markers of major depressive disorder
Liu, X., Li, J., Zheng, P., Zhao, X., Zhou, C., Hu, C., Hou, X., Wang, H., Xie, P., & Xu, G. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9768-5 · Cited by 148
Anderson, H. D., Pace, W. D., Libby, A. M., West, D. R., & Valuck, R. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.024 · Cited by 147 · cited 1×
“duction of new, non-monoamine-based depression approaches, including the melatonergic mechanism [14] or glutamate method [15,16], has become increasingly”
BackgroundHernández, M. E., Mendieta, D., Martínez-Fong, D., Loría, F., Moreno, J., Estrada, I., Bojalil, R., & Pavón, L. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.001 · Cited by 140
The Fibroblast Growth Factor System and Mood Disorders
Turner, C. A., Akil, H., Watson, S. J., & Evans, S. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.026 · Cited by 131
The relationship between cortisol, stress and psychiatric illness: New insights using hair analysis
Herane Vives, A., De Angel, V., Papadopoulos, A., Strawbridge, R., Wise, T., Young, A. H., Arnone, D., & Cleare, A. J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.08.007 · Cited by 129 · cited 1×
“these indicate that hypercortisolemia is linked with stress and a recurrent attenuation of cortisol awakening responses [111,112].”
BackgroundNeuroimaging-based biomarkers for treatment selection in major depressive disorder
Dunlop, B. W., & Mayberg, H. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/bdunlop · Cited by 127 · cited 1×
“causing down-regulation of animal experiments in the BDNF pathways [62,63].”
BackgroundFischer, S., Strawbridge, R., Vives, A. H., & Cleare, A. J. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.180653 · Cited by 112
VEGF and depression: A comprehensive assessment of clinical data
Clark-Raymond, A., & Halaris, A. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.04.008 · Cited by 108 · cited 1×
“cial to the role as biomarkers for their presence in brain and peripheral circulation [67-70].”
BackgroundKambeitz, J. P., & Howes, O. D. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.07.034 · Cited by 96 · cited 1×
“ing of so-called lipid rafts [43], and the size and amount in lymphocytes in patients has dramatically increased in contrast with stable controls [44].”
BackgroundCoplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90 · cited 1×
“could prove to be a very potent one [30].”
BackgroundMetabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention
Hendrickx, H., McEwen, B. S., & Ouderaa, F. V. D. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.005 · Cited by 83 · cited 1×
“now being tested in the hair or fingernails [27] as well.”
BackgroundRedei, E. E., Andrus, B. M., Kwasny, M. J., Seok, J., Cai, X., Ho, J., & Mohr, D. C. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.66 · Cited by 83 · cited 1×
“preclinical investigated [42], no clinical trials have been carried out.”
BackgroundJorgensen, A., Krogh, J., Miskowiak, K., Bolwig, T. G., Kessing, L. V., Fink-Jensen, A., Nordentoft, M., Henriksen, T., Weimann, A., Poulsen, H. E., et al. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.011 · Cited by 74
Fornaro, M., Rocchi, G., Escelsior, A., Contini, P., & Martino, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.007 · Cited by 59 · cited 1×
“slight decreases along with therapy [86,87].”
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53 · cited 1×
“This complexity has direct consequences for our accuracy in the diagnosis and subtypes of depression [8], for”
Background
Cited by
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102
Milic, J., Jovic, S., & Sapic, R. (2025) · Genes · doi:10.3390/genes16050487 · Cited by 19
“These findings underscore the urgent need for the development of an integrated biomarker panel that captures the biological diversity of MDD, enabling more precise diagnosis and individualized therapeutic strategies [27].”
(2023) · doi:10.1038/s44184-023-00024-z · Cited by 12
Metadata
- Authors
- Malik, S., Singh, R., Arora, G., Dangol, A., & Goyal, S.
- Venue
- Clinical Psychopharmacology and Neuroscience
- Published
- 2021-02-28
- Volume
- 19
- Issue
- 1
- Pages
- 12-25
- ISSN
- 1738-1088 (ISSN-L)
- 2093-4327
- OpenAlex
- W3121510462
- Cited by
- 42
- References
- 52
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.